<code id='372A6DB021'></code><style id='372A6DB021'></style>
      • <acronym id='372A6DB021'></acronym>
      <center id='372A6DB021'><center id='372A6DB021'><tfoot id='372A6DB021'></tfoot></center><abbr id='372A6DB021'><dir id='372A6DB021'><tfoot id='372A6DB021'></tfoot><noframes id='372A6DB021'>
      • <optgroup id='372A6DB021'><strike id='372A6DB021'><sup id='372A6DB021'></sup></strike><code id='372A6DB021'></code></optgroup>
        5. <b id='372A6DB021'><label id='372A6DB021'><select id='372A6DB021'><dt id='372A6DB021'><span id='372A6DB021'></span></dt></select></label></b><u id='372A6DB021'></u>
          <i id='372A6DB021'><strike id='372A6DB021'><tt id='372A6DB021'><pre id='372A6DB021'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-29 15:39:58 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：636
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Beam Therapeutics to lay off 20% of its staff, re
                                
                            
          Next article：  
                                      
                                          FDA approval of Sarepta Duchenne genetic therapy gives me hope
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles